Applications of Cannabinoids in Neuropathic Pain: An Updated Review.

IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2024-01-01 DOI:10.1615/CritRevTherDrugCarrierSyst.2022038592
Peggy Arthur, Anil Kumar Kalvala, Sunil Kumar Surapaneni, Mandip Sachdeva Singh
{"title":"Applications of Cannabinoids in Neuropathic Pain: An Updated Review.","authors":"Peggy Arthur, Anil Kumar Kalvala, Sunil Kumar Surapaneni, Mandip Sachdeva Singh","doi":"10.1615/CritRevTherDrugCarrierSyst.2022038592","DOIUrl":null,"url":null,"abstract":"<p><p>Neuropathic pain is experienced due to injury to the nerves, underlying disease conditions or toxicity induced by chemotherapeutics. Multiple factors can contribute to neuropathic pain such as central nervous system (CNS)-related autoimmune and metabolic disorders, nerve injury, multiple sclerosis and diabetes. Hence, development of pharmacological interventions to reduce the drawbacks of existing chemotherapeutics and counter neuropathic pain is an urgent unmet clinical need. Cannabinoid treatment has been reported to be beneficial for several disease conditions including neuropathic pain. Cannabinoids act by inhibiting the release of neurotransmitters from presynaptic nerve endings, modulating the excitation of postsynaptic neurons, activating descending inhibitory pain pathways, reducing neural inflammation and oxidative stress and also correcting autophagy defects. This review provides insights on the various preclinical and clinical therapeutic applications of cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) in various diseases and the ongoing clinical trials for the treatment of chronic and acute pain with cannabinoids. Pharmacological and genetic experimental strategies have well demonstrated the potential neuroprotective effects of cannabinoids and also elaborated their mechanism of action for the therapy of neuropathic pain.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"41 1","pages":"1-33"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228808/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022038592","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Neuropathic pain is experienced due to injury to the nerves, underlying disease conditions or toxicity induced by chemotherapeutics. Multiple factors can contribute to neuropathic pain such as central nervous system (CNS)-related autoimmune and metabolic disorders, nerve injury, multiple sclerosis and diabetes. Hence, development of pharmacological interventions to reduce the drawbacks of existing chemotherapeutics and counter neuropathic pain is an urgent unmet clinical need. Cannabinoid treatment has been reported to be beneficial for several disease conditions including neuropathic pain. Cannabinoids act by inhibiting the release of neurotransmitters from presynaptic nerve endings, modulating the excitation of postsynaptic neurons, activating descending inhibitory pain pathways, reducing neural inflammation and oxidative stress and also correcting autophagy defects. This review provides insights on the various preclinical and clinical therapeutic applications of cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) in various diseases and the ongoing clinical trials for the treatment of chronic and acute pain with cannabinoids. Pharmacological and genetic experimental strategies have well demonstrated the potential neuroprotective effects of cannabinoids and also elaborated their mechanism of action for the therapy of neuropathic pain.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大麻酚类药物在神经性疼痛中的应用:最新综述。
神经性疼痛是由于神经损伤、潜在疾病或化疗药物引起的毒性而引起的。多种因素可导致神经性疼痛,如中枢神经系统相关的自身免疫和代谢紊乱、神经损伤、多发性硬化症和糖尿病。因此,开发药物干预措施以减少现有化疗药物和对抗神经性疼痛的缺点是一个迫切需要满足的临床需求。据报道,大麻素治疗对包括神经性疼痛在内的多种疾病有益。大麻素的作用是抑制突触前神经末梢的神经递质释放,调节突触后神经元的兴奋,激活下行抑制性疼痛通路,减少神经炎症和氧化应激,并纠正自噬缺陷。这篇综述深入了解了大麻二酚(CBD)、大麻酚(CBG)和大麻素(CBN)在各种疾病中的各种临床前和临床治疗应用,以及正在进行的大麻素治疗慢性和急性疼痛的临床试验。药理学和遗传学实验策略已经很好地证明了大麻素的潜在神经保护作用,并阐述了其治疗神经性疼痛的作用机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.50
自引率
18.50%
发文量
27
审稿时长
>12 weeks
期刊介绍: Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.
期刊最新文献
Current Review on Nanophytomedicines in the Treatment of Oral Cancer: Recent Trends and Treatment Prospects. Recent Updates on Phytopharmaceuticals-Based Novel Phytosomal Systems and Their Clinical Trial Status: A Translational Perspective. Enhancing Microemulsion based Therapeutic Drug Delivery: Exploring Surfactants, Co-surfactants, and Quality by Design Strategies within Pseudo-ternary Phase Diagrams NOVEL DRUG DELIVERY TOOLS FOR BETTER PERMEATION AND SKIN CANCER TREATMENT Nanobiocatalysts and Nanozymes: Enzyme-Inspired Nanomaterials for Industrial and Biomedical Applications
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1